Immunotherapy (IO) has significantly improved survival rates and quality of life in comparison with tyrosine kinase inhibitors for patients with advanced renal cell carcinoma (aRCC).
We estimated the economic impact of incorporating IO into the National High-Cost Drug Financing Agency list of reimbursed medications for treating intermediate- and poor-risk aRCC in Uruguay.
